Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074035 · ClinicalTrials.gov registry record · Phase 2
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase 2 study of Graft-Versus-Host Disease, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 16
- Study locations
NCT00074035: Completed Phase 2 study of Graft-Versus-Host Disease, sponsored by Alliance for Clinical Trials in Oncology.
NCT00074035 is a Phase 2 study of Graft-Versus-Host Disease that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 39 participants, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (52% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00074035, a Phase 2 study of Graft-Versus-Host Disease, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 16
- Study locations
Study Summary
RATIONALE: Pentostatin may be effective in treating chronic graft-versus-host disease by stopping the immune system from rejecting donor stem cells or donor white blood cells. PURPOSE: This phase II trial is studying how well pentostatin works in treating patients with chronic graft-versus-host disease that is refractory (not responsive) to treatment with steroids.
Primary Outcome
Percentage of participants who had a complete or partial response defined by the Hopkins scoring system. A complete response is defined as the disappearance of signs and symptoms of chronic GVHD in all involved systems that is sustained for at lest 4 weeks. A partial response is an improvement by 2 or more points in at least one system score, which is sustained for at least 4 weeks, with no signs of worsening in others.
Conditions Studied
Interventions
- DRUG pentostatin
Study Locations (16)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
- Fox Chase Cancer Center - Philadelphia - Philadelphia
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital - Pittsburgh
Delaware
- Tunnell Cancer Center at Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
Illinois
- University of Illinois Cancer Center - Chicago
- University of Chicago Cancer Research Center - Chicago
Maryland
- Greenebaum Cancer Center at University of Maryland Medical Center - Baltimore
- Union Hospital Cancer Program at Union Hospital - Elkton
North Carolina
- Duke Comprehensive Cancer Center - Durham
- Wake Forest University Comprehensive Cancer Center - Winston-Salem
Minnesota
- Mayo Clinic Cancer Center - Rochester
New Jersey
- Cancer Institute of New Jersey at Cooper - Voorhees - Voorhees Township
New York
- New York Weill Cornell Cancer Center at Cornell University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2003-12 |
| Est. Completion | 2014-11-01 |
| Phase | Phase 2 |
What the finished NCT00074035 record still lists
NCT00074035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 1 intervention - of which pentostatin is the first listed.
NCT00074035 lists 16 locations in 10 states (Pennsylvania, Delaware, Illinois).
Frequently Asked Questions
What is clinical trial NCT00074035 about?
NCT00074035 is a clinical study titled "Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease". RATIONALE: Pentostatin may be effective in treating chronic graft-versus-host disease by stopping the immune system from rejecting donor stem cells or donor white blood cells. PURPOSE: This phase II trial is studying how well pentostatin works in treating patients with chronic graft-versus-host dis...
What is the current status of trial NCT00074035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2003-12. Estimated completion is 2014-11-01.
What conditions does trial NCT00074035 study?
This clinical trial studies the following conditions: Graft-Versus-Host Disease.
What interventions are being tested in trial NCT00074035?
The interventions under investigation include: pentostatin (DRUG).
Who is sponsoring clinical trial NCT00074035?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00074035 being conducted?
This trial has 16 study locations across Delaware, Illinois, Maryland, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft-Versus-Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00074035's enrollment target sits among peer trials
39 19th of 38 higher than 20 of 38 other Graft-Versus-Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft-Versus-Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
RECRUITING · Phase 2
-
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
ACTIVE NOT RECRUITING · Phase 2
-
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia